Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Yuichiro Ohe, MD"'
Autor:
Masahiro Torasawa, MD, Tatsuya Yoshida, MD, PhD, Kouya Shiraishi, PhD, Naoko Goto, BS, Toshihide Ueno, PhD, Hitoshi Ichikawa, MD, PhD, Shigehiro Yagishita, MD, PhD, Shinji Kohsaka, MD, PhD, Yasushi Goto, MD, PhD, Yasushi Yatabe, MD, PhD, Akinobu Hamada, PhD, Hiroyuki Mano, MD, PhD, Yuichiro Ohe, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100657- (2024)
Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon
Externí odkaz:
https://doaj.org/article/5692dcec9c88419db79b30d6266edb38
Autor:
Yuki Takeyasu, MD, Tatsuya Yoshida, MD, Ken Masuda, MD, Yuji Matsumoto, MD, Yuki Shinno, MD, Yusuke Okuma, MD, Yasushi Goto, MD, Hidehito Horinouchi, MD, Noboru Yamamoto, MD, Yuichiro Ohe, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100636- (2024)
Introduction: Osimertinib (OSI), a third-generation EGFR tyrosine kinase inhibitor, is the standard treatment for patients with naive EGFR-mutant NSCLC. Nevertheless, information on how the mutation subtype affects disease progression after the failu
Externí odkaz:
https://doaj.org/article/2ca2a2673ed6490287b76ea50654af86
Autor:
Hideki Ikeda, MD, Joji Nagasaki, MD, PhD, Daiki Shimizu, MD, Yuki Katsuya, MD, PhD, Hidehito Horinouchi, MD, PhD, Yukio Hosomi, MD, PhD, Etsuko Tanji, MS, Takekazu Iwata, MD, PhD, Makiko Itami, MD, PhD, Masahito Kawazu, MD, PhD, Yuichiro Ohe, MD, PhD, Takuji Suzuki, MD, PhD, Yosuke Togashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100573- (2023)
Introduction: Unresectable or recurrent thymic epithelial tumors (TETs) have a poor prognosis, and treatment options are limited. This study aimed to investigate the immunologic significance of CD80/CD86 or major histocompatibility complex class II (
Externí odkaz:
https://doaj.org/article/e22f91bb33b34c45b99ef4b5ba01a266
Autor:
Hitomi Jo, MD, PhD, Tatsuya Yoshida, MD, PhD, Shigehiro Yagishita, MD, PhD, Mayu Ohuchi, PhD, Yuji Matsumoto, MD, PhD, Yuki Shinno, MD, PhD, Yusuke Okuma, MD, PhD, Yasushi Goto, MD, PhD, Hidehito Horinouchi, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhisa Takahashi, MD, PhD, Noriko Motoi, MD, PhD, Akinobu Hamada, PhD, Yuichiro Ohe, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100474- (2023)
Introduction: Immune checkpoint inhibitors (ICIs) induce long-term, durable responses in patients with advanced NSCLC. Nevertheless, these responses are limited to a few patients, and most responders have disease progression. The purpose of this stud
Externí odkaz:
https://doaj.org/article/fbc7fcbfc26745ea85440370d0442d63
Autor:
Yuichi Ozawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kouji Yamamoto, PhD, Kentaro Ito, MD, Hirotsugu Kenmotsu, MD, PhD, Hidetoshi Hayashi, MD, PhD, Takehito Shukuya, MD, PhD, Daichi Fujimoto, MD, PhD, Shunichi Sugawara, MD, PhD, Seiji Niho, MD, PhD, Yuichiro Ohe, MD, PhD, Hiroaki Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Katsuyuki Kiura, MD, PhD, Ichiro Yoshino, MD, PhD, Akihiko Gemma, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100317- (2022)
Introduction: Although data accumulated in clinical trials have higher accuracy compared with real-world data and are irreplaceably valuable, most previous clinical trial data have been left unused. Methods: The Japan Lung Cancer Society (JLCS) asked
Externí odkaz:
https://doaj.org/article/cf2d0ca2ab7547e2abd79d3f7eb16898
Autor:
Yuki Takeyasu, MD, Tatsuya Yoshida, MD, Ken Masuda, MD, Yuji Matsumoto, MD, Yuki Shinno, MD, Yusuke Okuma, MD, Yasushi Goto, MD, Hidehito Horinouchi, MD, Noboru Yamamoto, MD, Yuichiro Ohe, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100311- (2022)
Introduction: Lorlatinib (LOR) or pemetrexed-based chemotherapy (PEM) is the standard treatment after failure of a second-generation ALK tyrosine kinase inhibitor, such as alectinib, in patients with ALK-positive NSCLC. Nevertheless, there have been
Externí odkaz:
https://doaj.org/article/e34bc5fff85145d196a7f16895ceb314
Autor:
Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100171- (2021)
Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic
Externí odkaz:
https://doaj.org/article/3e75f1f8e2034c7bb7923044f4c4d8a7
Autor:
Kazuhiko Nakagawa, MD, PhD, Takashi Kijima, MD, PhD, Morihito Okada, MD, PhD, Masahiro Morise, MD, PhD, Motoyasu Kato, MD, PhD, Katsuya Hirano, MD, Nobukazu Fujimoto, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Hiroshi Yokouchi, MD, PhD, Yuichiro Ohe, MD, PhD, Toyoaki Hida, MD, PhD, Keisuke Aoe, MD, PhD, Takumi Kishimoto, MD, PhD, Masato Hirokawa, MSc, Hironori Matsuki, MEng, Yutaro Kaneko, BSc, Taketo Yamada, MD, PhD, Chikao Morimoto, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100178- (2021)
Introduction: YS110, a humanized monoclonal antibody with a high affinity to CD26, exhibited promising antitumor activity and was generally well-tolerated in the phase 1 part of a phase 1 and 2 Japanese trial in patients with malignant pleural mesoth
Externí odkaz:
https://doaj.org/article/e0dd33bf32bd4e94a6baf9946819d8b9
Autor:
Nobukazu Fujimoto, MD, PhD, Morihito Okada, MD, PhD, Takashi Kijima, MD, PhD, Keisuke Aoe, MD, PhD, Terufumi Kato, MD, Kazuhiko Nakagawa, MD, PhD, Yuichiro Takeda, MD, PhD, Toyoaki Hida, MD, PhD, Kuninobu Kanai, MD, PhD, Jun Hirano, MPharm, Yuichiro Ohe, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100135- (2021)
Introduction: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-liga
Externí odkaz:
https://doaj.org/article/6daaa024a9364fefa2c9b2eb6842a85c
Autor:
Tairo Kashihara, MD, PhD, Yuko Nakayama, MD, PhD, Kimiteru Ito, MD, PhD, Yuko Kubo, MD, Kae Okuma, MD, PhD, Satoshi Shima, MD, Satoshi Nakamura, PhD, Kana Takahashi, MD, PhD, Koji Inaba, MD, PhD, Naoya Murakami, MD, PhD, Hiroshi Igaki, MD, PhD, Yuichiro Ohe, MD, PhD, Masahiko Kusumoto, MD, PhD, Jun Itami, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 1, Pp 100606- (2021)
Purpose: Adjuvant durvalumab has become a standard treatment after chemoradiation therapy for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Accordingly, predicting radiation pneumonitis (RP) requiring steroidal treatment (ster
Externí odkaz:
https://doaj.org/article/2f8b19d7fa1d4ab4a6e39c0bbdcb2aa6